Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2014

Primary Completion Date

December 1, 2024

Study Completion Date

December 12, 2025

Conditions
Carcinoma, Non-Small Cell LungEGFR Gene Mutation
Interventions
DRUG

Gemcitabine platinum combined with erlotinib

patients will received a 28 days gemcitabine platinum combined with erlotinib scheme, after 4 cycles combined chemotherapy, patients will receive erlotinib for maintain treatment until progression disease.Gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for day 9-21 during combined chemotherapy, 150mg/day, then erlotinib should be used daily until patients develop progression disease.

Trial Locations (1)

Unknown

RECRUITING

Hunan Province Tumor Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER

NCT02098954 - Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers | Biotech Hunter | Biotech Hunter